Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product
Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development Strategy Into Synergistic Adjacencies
Transaction Includes Exclusive Period To Evaluate And Negotiate To Acquire A Rare Epilepsy Compound In Development
Acquisition Expected to be EBITDA and EPS Accretive in 2023
https://finance.yahoo.com/news/catalyst-pharmaceuticals-acquire-u-commercial-211000463.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.